MedTrace Logo

Myasthenia Gravis Registry in China

NCT06241521 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2024-02-05

No results posted yet for this study

Summary

Myasthenia gravis (MG) is an autoimmune disease caused by dysfunction at the neuromuscular junction, characterized by partial or generalized skeletal muscle weakness and fatigability. The estimated annual incidence rate of MG in China is 0.68/100,000, with a high rate of relapse and poor treatment compliance. This study is a prospective, observational, multi-center patient registry across China. To support standardized management and follow-up of MG patients in China, a Cloud-based MG Patient Management Platform (CN MG Base) was established in September 2023 with the support of the Chinese Rare Diseases Alliance. The platform aims to collect longitudinal clinical data including demographic information, age of onset, medical history, comorbidities, medication usage, treatment responses, and others. It is intended to collect newly registered MG cases each year and follow up with these patients at one-year intervals for ten years

Conditions

Sponsors & Collaborators

  • China Alliance for Rare Diseases

    collaborator UNKNOWN

  • National Center for Neurological Disorders (China)

    collaborator UNKNOWN

  • China myasthenia gravis collaborating group (CMGCG)

    collaborator UNKNOWN

  • Huashan Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2034-02-01
Completion
2035-01-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06241521 on ClinicalTrials.gov